CS
VYNT

Credit Suisse’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Credit Suisse’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-67
Closed -$9K – 4054
2018
Q2 		$9K Buy
+67
New +$10.1K ﹤0.01% 3940

Other funds holding VYNT

PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
FCM
Fairbanks Capital Management Rancho Santa Fe, California $169M AUM 12.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DM
Diker Management New York $130M AUM 97.77% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Credit Suisse's VYNT Position: Q3 2018 in Review

Credit Suisse sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q3 2018, closing a stake of 67 shares — an estimated $9K sold.

Credit Suisse first reported a position in VYNT in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 26 funds tracked by Wall St. Rank hold VYNT as of Q3 2018.

  • Credit Suisse reported no remaining Vyant Bio, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Credit Suisse sold 67 Vyant Bio, Inc. Common Stock shares in Q3 2018, an estimated $9K.
  • Credit Suisse first reported a position in Vyant Bio, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Credit Suisse's Vyant Bio, Inc. Common Stock position peaked at $9K in Q2 2018.
  • 26 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q3 2018.

Based on Credit Suisse's 13F filing for Q3 2018, filed 13 Nov 2018.